2026-04-29T00:59:57Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/226642024-11-28T18:08:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16968col_20.500.12105_16983
Repisalud
author
Razquin, Cristina
author
Ruiz-Canela, Miguel
author
Clish, Clary B
author
Li, Jun
author
Toledo, EstefanÃa
author
Dennis, Courtney
author
Liang, Liming
author
Salas-Huetos, Albert
author
Pierce, Kerry A
author
Guasch-Ferre, Marta
author
Corella, Dolores
author
Ros, Emilio
author
Estruch, Ramon
author
Gomez-Gracia, Enrique
author
Fito, Montserrat
author
Lapetra, Jose
author
Romaguera, Dora
author
Alonso-Gomez, Angel
author
Serra-Majem, Lluis
author
Salas-Salvado, Jordi
author
Hu, Frank B
author
Martinez-Gonzalez, Miguel A
2024-09-10T13:06:55Z
2024-09-10T13:06:55Z
2019-11-13
Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, et al. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol. 2019 Nov 13;18(1):151.
http://hdl.handle.net/20.500.13003/13075
https://hdl.handle.net/20.500.12105/22664
31722714
10.1186/s12933-019-0958-2
1475-2840
Cardiovascular Diabetology
2-s2.0-85074961499
497753100001
L629863561
Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
eng
Biomarkers
Metabolites
Cardiovascular disease
Type 2 diabetes
Dietary intervention
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
research article